Activation of receptor for advanced glycation end products - A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis

被引:641
|
作者
Schmidt, AM
Yan, SD
Wautier, JL
Stern, D
机构
[1] Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA
[3] Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA
[4] Columbia Univ Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA
[5] Columbia Univ Coll Phys & Surg, Dept Cellular Biophys, New York, NY 10032 USA
[6] UFR Lariboisiere St Louis, Lab Biol Vasc & Cellulaire, Paris, France
关键词
glycoxidation; diabetes; nuclear factor-kappa B; inflammation; amyloid;
D O I
10.1161/01.RES.84.5.489
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of cell surface molecules and engages diverse ligands relevant to distinct pathological processes. One class of RAGE ligands includes glycoxidation products, termed advanced glycation end products, which occur in diabetes, at sites of oxidant stress in tissues, and in renal failure and amyloidoses. RAGE also functions as a signal transduction receptor for amyloid beta peptide, known to accumulate in Alzheimer disease in both affected brain parenchyma and cerebral vasculature. Interaction of RAGE with these ligands enhances receptor expression and initiates a positive feedback loop whereby receptor occupancy triggers increased RAGE expression, thereby perpetuating another wave of cellular activation. Sustained expression of RAGE by critical target cells, including endothelium, smooth muscle cells, mononuclear phagocytes, and neurons, in proximity to these ligands, sets the stage for chronic cellular activation and tissue damage. In a model of accelerated atherosclerosis associated with diabetes in genetically manipulated mice, blockade of cell surface RAGE by infusion of a soluble, truncated form of the receptor completely suppressed enhanced formation of vascular lesions. Amelioration of atherosclerosis in these diabetic/atherosclerotic animals by soluble RAGE occurred in the absence of changes in plasma lipids or glycemia, emphasizing the contribution of a lipid- and glycemia-independent mechanism(s) to atherogenesis, which we postulate to be interaction of RAGE with its ligands. Future studies using mice in which RAGE expression has been genetically manipulated and with selective low molecular weight RAGE inhibitors will be required to definitively assign a critical role for RAGE activation in diabetic vasculopathy. However, sustained receptor expression in a microenvironment with a plethora of ligand makes possible prolonged receptor stimulation, suggesting that interaction of cellular RAGE with its ligands could be a factor contributing to a range of important chronic disorders.
引用
收藏
页码:489 / 497
页数:9
相关论文
共 50 条
  • [31] Endogenous advanced glycation end products in the pathogenesis of chronic diabetic complications
    Mengstie, Misganaw Asmamaw
    Abebe, Endeshaw Chekol
    Teklemariam, Awgichew Behaile
    Mulu, Anemut Tilahun
    Agidew, Melaku Mekonnen
    Azezew, Muluken Teshome
    Zewde, Edgeit Abebe
    Teshome, Assefa Agegnehu
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [32] Receptor for advanced glycation end products (RAGE) in vascular and inflammatory diseases
    Mahajan, Nitin
    Dhawan, Veena
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (03) : 1788 - 1794
  • [33] THE INFLUENCE OF ADVANCED GLYCATION END PRODUCTS AND THEIR RECEPTORS ON THE PROGRESSION OF DIABETIC ERECTILE DYSFUNCTION
    Lin, Wang
    JOURNAL OF SEXUAL MEDICINE, 2013, 10 : 230 - 230
  • [34] Sexual Dysfunction in Diabetic Patients: Τhe Role of Advanced Glycation End Products
    Peppa, Melpomeni
    Manta, Aspasia
    CURRENT DIABETES REVIEWS, 2024, 20 (02) : 1 - 9
  • [35] Integral Role of Receptor for Advanced Glycation End Products (RAGE) in Nondiabetic Atherosclerosis
    Uekita, Hironori
    Ishibashi, Toshiyuki
    Sugimoto, Koichi
    Shlomi, Masashi
    Yamagishi, Shoichi
    Koyama, Hidenori
    Takeishi, Yasuchika
    CIRCULATION RESEARCH, 2009, 105 (07) : E44 - E44
  • [36] Integral role of receptor for advanced glycation end products (RAGE) in nondiabetic atherosclerosis
    Uekita, Hironori
    Ishibashi, Toshiyuki
    Shiomi, Masashi
    Koyama, Hidenori
    Ohtsuka, Shukuko
    Yamamoto, Hiroshi
    Yamagishi, Shoichi
    Inoue, Hiroyoshi
    Itabe, Hiroyuki
    Sugimoto, Koichi
    Kamioka, Masashi
    Ohkawara, Hiroshi
    Wada, Ikuo
    Takeishi, Yasuchika
    FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, 2019, 65 (03) : 109 - 121
  • [37] Diabetic erythrocytes bearing advanced glycation end products induce vascular dysfunctions
    Wautier, JL
    Wautier, MP
    Chappey, O
    Zoukourian, C
    Guillausseau, PJ
    Capron, L
    CLINICAL HEMORHEOLOGY, 1996, 16 (05): : 661 - 667
  • [38] Advanced glycation end products and diabetic retinopathy
    Ross Milne
    Seymour Brownstein
    Amino Acids, 2013, 44 : 1397 - 1407
  • [39] Activation of Receptor for Advanced Glycation End Products Induces Osteogenic Differentiation of Vascular Smooth Muscle Cells
    Suga, Toshihiro
    Iso, Tatsuya
    Shimizu, Takehisa
    Tanaka, Toru
    Yamagishi, Sho-ichi
    Takeuchi, Masayoshi
    Imaizumi, Tsutomu
    Kurabayashi, Masahiko
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2011, 18 (08) : 670 - 683
  • [40] Advanced Glycation End Products and Diabetic Retinopathy
    Chen, M.
    Curtis, T. M.
    Stitt, A. W.
    CURRENT MEDICINAL CHEMISTRY, 2013, 20 (26) : 3234 - 3240